石四藥集團(02005.HK):阿比多爾被國家衞健委列入新冠肺炎診療方案(試行第八版)
格隆匯 8 月 19日丨石四藥集團(02005.HK)發佈公告,集團產品阿比多爾被國家衞生健康委員會於2020年8月18日列入新型冠狀病毒肺炎診療方案(試行第八版)。該診療方案再次確認阿比多爾被用於抗病毒治療。
此外,石家莊四藥有限公司(公司的國內全資附屬公司)已取得國家藥品監督管理局有關瑞舒伐他汀鈣片(10mg)的藥品生產註冊批件。瑞舒伐他汀鈣屬於新分類化學藥品4類,主要用於治療原發性高膽固醇血癥或混合型血脂異常症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.